A study of lipid profile in non-diabetic chronic kidney disease

Veeren Ganta, Radha Priya Yalamanchi, Mahanta KC, Biswajit Sahu, Kota Raghvendar, Gudipati Anusha, Bharadwaj Bachu, C. Raghavendra Reddy


Background: The present study focused on finding an approximate prevalence of dyslipidemia in the target reference population and the association with staging and management strategy used. An effort was also made to know the alteration in different lipoprotein fractions in chronic kidney disease. The objective of the study was to study the lipid profile in non-diabetic patients with chronic kidney disease.

Methods: The study was conducted in Ispat general hospital, Rourkela and data was collected from January 2014 to September 2015. Patients who were diagnosed with Chronic Kidney Disease admitted into the medical ward and dialysis unit of Ispat General Hospital, Rourkela, Odisha, who had willingly given their informed written consent for this study were the source of data. For diagnosis of CKD, history and clinical features with supportive biochemical and radiological evidence were taken as criteria. Patients with already known diabetes mellitus were excluded.

Results: The prevalence of dyslipidemia in CKD was found to be about 65.%. And the prevalence was increasing with the increase in severity of the disease. There was a significant rise in the serum triglyceride concentration in the study population. This abnormality was followed by a fall in HDL cholesterol and rise in the total Serum cholesterol in patients suffering from CKD. On comparing patients with CKD on hemodialysis with that on conservative management there is a significant prevalence of dyslipidemia in the Hemodialysis group. There is a significantly higher level of triglycerides and Serum cholesterol and a significantly lower level of HDL cholesterol in the hemodialysis group.

Conclusions: The high prevalence of lipid abnormalities in CKD may accelerate the progression of CVD and increase the mortality of patients. Hence it is worthwhile to test and detect patients at high risk early on and manage accordingly.


CKD, Lipid profile, Non diabetic

Full Text:



Coresh J, Astor BC, Greene T. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination Survey. Am J Kidney Dis. 2003;41(1):1-12.

Coresh J, Selvin E, Stevens LA. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47.

Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(3):S112-9.

Parfrey PS, Foley RN, Harnett JD. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49(5):1428-34.

Baugh ME, Stoltz ML, Vanbeber AD, Gorman MA. Are lipid values and BMI related to hospitalizations in the hemodialysis population. J Ren Nutr. 2001;11(1):37-45.

Cheng SC, Chu TS, Huang KY. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int. 2001;21(3):282-9.

Bakkaloglu SA, Ekim M, Tumer N, Soylu K. The effect of CAPD on the lipid profile of pediatric patients. Perit Dial Int. 2000;20(5):568-71.

Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001;38:S26-9.

Harper CR, Jacobson TA. Managing Dyslipidemia in Chronic Kidney Disease. J of the Am College of Cardiology. 2008;51(25):2375-84.

Poudel B, Yadav BK, Jha B, Raut KB. Dyslipidemia in chronic kidney disease in Nepalese population. Mymensingh Med J. 2013;22(1):157-63.

Saroj K, Rajendra KC, Sharad G. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients. Endocr Disord. 2015;15:65.

Staprans I, Felts JM, Zacherle B. Apoprotein composition of plasma lipoprotein in uremic patients on hemodialysis. Clin Chem Acta. 1979;93:135-43.

Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor related protien (LRP) in chronic renal failure. Kidney Int. 2005;67(3):1028-32.

Anderson SG, Diego L, Brenner BM. Renal and systemic manifestations and glomerular disease. 4th ed. Philadelphia: W.B.Saunders Company. 1991.

Appel G. Lipid abnormalities in renal disease. Kidney Intl. 1991;39(1):169-83.

Andrew PG, Deborah M Applebaum-Bowden, Edwin LB et al. Increase lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med. 1979;301:1073-6.

Jayson R, Micahel A, Cidio C, Brook JG. Defective high density lipoprotein composition in patients on chronic hemodialysis- A possible mechanism for accelerated atherosclerosis. N Engl J Med. 1978;299:1326-9.

Kronenberg F, Lingenhel A, Neyer U. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int. 2003;(84):S113-6.

Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1-7.